Aether Industries Ltd
NSE:AETHER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (62.1), the stock would be worth ₹1 656.5 (40% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 44.3 | ₹1 179.8 |
0%
|
| 3-Year Average | 62.1 | ₹1 656.5 |
+40%
|
| 5-Year Average | 60 | ₹1 600.07 |
+36%
|
| Industry Average | 21.2 | ₹564.18 |
-52%
|
| Country Average | 17.7 | ₹470.84 |
-60%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₹128.5B
|
/ |
Jan 2026
₹3.5B
|
= |
|
|
₹128.5B
|
/ |
Mar 2026
₹3.8B
|
= |
|
|
₹128.5B
|
/ |
Mar 2027
₹4.9B
|
= |
|
|
₹128.5B
|
/ |
Mar 2028
₹6.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
A
|
Aether Industries Ltd
NSE:AETHER
|
156.4B INR | 44.3 | 72.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 28.7 | 42.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 17.1 | 26.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 16.6 | 30.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 10 | 16.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 12.6 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 8.2 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 7.8 | 20.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 7.2 | 17 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 27.8 |
| Max | 47 834.4 |
Other Multiples
Aether Industries Ltd
Glance View
In the bustling landscape of India's chemical industry, Aether Industries Ltd. charts a path defined by innovation and precision. Founded on the vision of seamlessly marrying chemistry with technology, Aether has carved out a niche as a specialty chemicals manufacturer. The company focuses on high-value chemistries that cater to sectors like pharmaceuticals, agrochemicals, and material sciences. Leveraging a robust research and development framework, Aether crafts complex, multi-step synthesis processes that elevate their products above commodity chemicals. This innovation-focused approach allows them to serve global giants across diverse industries, fostering partnerships that bolster their reputation for quality and reliability. What truly sets Aether Industries apart is its adeptness at generating significant value from its intellectual capital. Rather than merely churning out chemicals, Aether emphasizes offering bespoke solutions tailored to their clients' unique requirements. By investing heavily in their R&D capabilities, they continually push the boundaries of what's possible with chemical compounds. Their financial engine is fueled by a strategic blend of direct sales of specialty chemicals, licensing of proprietary technologies, and long-term supply agreements. This trifecta ensures a steady and resilient revenue stream, while their commitment to operational excellence and sustainability further strengthens their market position, making them a pivotal player in the specialty chemicals domain.
